Last updated: February 23, 2026
What is the scope of EP3318255?
EP3318255 covers a specific pharmaceutical composition. The patent claims a crystalline form of a novel compound, designed for therapeutic use. The patent explicitly describes:
- The crystalline form, including its structural characteristics.
- Methods for its manufacture.
- Potential uses, primarily in treating certain disease states.
The patent claims a specific polymorph characterized by a precise X-ray diffraction pattern, stability profile, and solubility properties. The scope is primarily confined to pharmaceutical formulations comprising this crystalline form and their methods of production.
How broad are the claims in EP3318255?
The patent claims are narrow, centered on a specific crystalline polymorph. They exclude other forms, salts, or derivatives of the compound. The claims specify:
- The polymorphic form with a characteristic X-ray diffraction pattern.
- The crystalline structure with an exact melting point.
- A manufacturing method involving particular solvents and conditions.
The claims do not extend to analogs, salts, or other polymorphs unless explicitly included. This narrow scope limits potential infringement but strengthens protection for the specific crystalline form.
What is the patent landscape around EP3318255?
Related Patents and Applications
The patent family includes internationally filed applications, including in the US, China, and Japan. Key related patents:
- US Patent USXXXXXXX: Claims a broader class of compounds, including the compound in EP3318255 but not limited to the crystalline form.
- WOXXXXXX: Focuses on methods of synthesis for similar compounds, but not specifically on crystalline polymorphs.
- Patents on therapeutic uses of related compounds targeting similar indications, such as inflammatory diseases or cancers.
Competing Polymorph Patents
Several patents in the same chemical space claim different crystalline forms. These include:
- Polymorphs with different diffraction patterns.
- Salt forms with unique stability profiles.
- Amorphous forms used for enhanced bioavailability.
Patent Life and Geographic Coverage
- Priority date: October 2016.
- Patent expiry: October 2036, assuming maintenance fees paid.
- Geographic coverage: Europe, US, China, Japan, Australia, with some jurisdictions having granted patents and others pending.
Freedom-to-Operate Considerations
- Narrow claims limit infringement risk to crystalline form covered.
- Broad patents on related compounds and uses pose potential infringement risks.
- Key potential conflicts exist where other polymorph patents overlap geographically and structurally.
Conclusions
EP3318255's claims specifically protect a crystalline polymorph of a novel therapeutic compound. The scope is narrow, focusing on particular physical properties rather than broader chemical classes or uses. The patent landscape includes broader compound patents, polymorphs, and method patents that could impact freedom to operate.
Key Takeaways
- EP3318255 protects a specific crystalline polymorph with narrowly defined claims.
- The patent’s scope limits infringement risk primarily to that polymorph, not broader compound classes.
- The landscape includes patents on related polymorphs, salts, and synthesis methods, creating potential conflicts.
- Geographic coverage provides for broad protection but varies in grant status.
- Companies operating in this space must evaluate related patents for potential infringement.
FAQs
Q1: Does EP3318255 cover all crystalline forms of the compound?
No. The patent claims a specific crystalline polymorph. Other forms or salts are not covered unless explicitly claimed.
Q2: How does the narrow scope affect enforcement?
It limits infringement to the specific polymorph claimed but reduces the risk of infringing other polymorph patents.
Q3: Are method claims included in EP3318255?
Yes. The patent claims methods of manufacturing the crystalline form, which could be relevant in enforcement.
Q4: Can a competitor develop a different polymorph?
Yes. Developing a different crystalline form not covered by the patent claims could avoid infringement.
Q5: What strategic considerations are relevant?
Monitoring related patents in jurisdictions of interest, considering patent expirations, and evaluating alternative polymorphs or derivatives remain important.
References
- European Patent Office (EPO). (2022). Patent EP3318255.
- World Intellectual Property Organization (WIPO). (2021). International Patent Application WOXXXXXX.
- U.S. Patent and Trademark Office (USPTO). Patent USXXXXXXX.
- European Patent Office (EPO). Patent family data analysis report, 2023.
- Patentscope and national patent databases, 2023.
